A
Anthony H. Gershlick
Researcher at University of Leicester
Publications - 265
Citations - 22767
Anthony H. Gershlick is an academic researcher from University of Leicester. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 52, co-authored 259 publications receiving 20014 citations. Previous affiliations of Anthony H. Gershlick include University Hospitals of Leicester NHS Trust & Blackpool Victoria Hospital.
Papers
More filters
Journal ArticleDOI
ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation
Stefan James,Dan Atar,Luigi P. Badano,Carina Blomström Lundqvist,Michael A. Borger,Anthony H. Gershlick,Kurt Huber,Peter Jüni,Mattie J. Lenzen,Kenneth W. Mahaffey,Marco Valgimigli +10 more
TL;DR: The once-in-a-lifetime treatment with Abciximab Intracoronary for acute coronary syndrome and a second dose intravenously for atrial fibrillation is recommended for adults with high blood pressure.
Journal ArticleDOI
Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS)
Joachim Schofer,Michael Schlüter,Anthony H. Gershlick,William Wijns,Eulogio García,Erick Schampaert,Günter Breithardt +6 more
TL;DR: Sirolimus-eluting stents are better than bare-metal stents for treatment of single long atherosclerotic lesions in a coronary vessel smaller than 3 mm in diameter.
Journal ArticleDOI
Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS).
TL;DR: In this article, a 28-day regimen of either 300mg clopidogrel loading dose and 325 mg/d aspirin plus 250 mg BID ticlopidine plus aspirin was used for coronary stent placement.
Journal ArticleDOI
Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease
Gregg W. Stone,Joseph F. Sabik,Patrick W. Serruys,Charles A. Simonton,Philippe Généreux,John D. Puskas,David E. Kandzari,Marie Claude Morice,Nicholas Lembo,W. Morris Brown,David P. Taggart,Adrian P. Banning,Béla Merkely,Ferenc Horkay,Piet W. Boonstra,Ad J. van Boven,Imre Ungi,Gábor Bogáts,Samer Mansour,Nicolas Noiseux,Manel Sabaté,José L. Pomar,Mark Hickey,Anthony H. Gershlick,Paweł Buszman,Andrzej Bochenek,Erick Schampaert,Pierre Pagé,Ovidiu Dressler,Ioanna Kosmidou,Roxana Mehran,Stuart J. Pocock,A. Pieter Kappetein +32 more
TL;DR: In patients with left main coronary artery disease and low or intermediate SYNTAX scores by site assessment, PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the composite end point of death, stroke, or myocardial infarction at 3 years.
Journal ArticleDOI
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Robert W. Yeh,Robert W. Yeh,Eric A. Secemsky,Dean J. Kereiakes,Sharon-Lise T. Normand,Anthony H. Gershlick,Anthony H. Gershlick,David J. Cohen,John A. Spertus,John A. Spertus,Philippe Gabriel Steg,Philippe Gabriel Steg,Donald E. Cutlip,Donald E. Cutlip,Michael J. Rinaldi,Edoardo Camenzind,William Wijns,Patricia Apruzzese,Yang Song,Joseph M. Massaro,Joseph M. Massaro,Laura Mauri,Laura Mauri +22 more
TL;DR: A clinical decision tool to identify patients expected to derive benefit vs harm from continuing thienopyridine beyond 1 year after percutaneous coronary intervention is developed to inform dual antiplatelet therapy duration.